Figure 6
Inhibition of COX-2 or TGF-β recovered immune-suppression by HNSCC cell line Sa-3 pretreated with erlotinib. EGFR875–889-reactive CD4+ T cell clone M8 was tested for its capacity to recognize erlotinib (1 μM)-pretreated Sa-3 with or without (A) celecoxib (10μM) and (B) anti-TGF-β antibody (10 μg) by quantification of IFN-γ production. Columns without bars had SD of <10% of mean values. Results are representative of three separate experiments. *p < 0.05.